Status
Conditions
Treatments
About
The goal of this observational study is to learn about the treatment effectiveness of physician's choice of chemotherapy and the immune checkpoint inhibitor (ICI)-based therapy in patients with relapsed/refractory ovarian clear cell carcinoma (OCCC), and compare the treatment response with the phase II, single-arm clinical trial INOVA to investigate the efficacy of combinational therapy of sintilimab plus bevacizumab. The main questions it aims to answer are:
Participants will be respectively retrieved and extracted de-identified, longitudinal electronic health records (EHR)-derived data.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
1.Histological evidence of non-ovarian clear cell carcinoma.
150 participants in 2 patient groups
Loading...
Central trial contact
Qinglei Gao, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal